🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to clarify the impact of rituximab on clinical...
Status
Completed
Location
Chonbuk National University Hospital
Start Date
2011-08
Trial ID
NCT01448096
Treatments Being Tested
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab...
Status
Completed
Location
George Washington University
Start Date
2017-10-04
Trial ID
NCT03283202
Treatments Being Tested
This open-label, single arm study will evaluate the safety of obinutuzumab ...
Status
Completed
Location
Rocky Mountain Cancer Center; Medical Oncology
Start Date
2019-02-26
Trial ID
NCT03817853
This is a prospective, multicenter, single arm, phase II trial in patients ...
Status
Active Not Recruiting
Location
Ospedale di Castelfranco Veneto - Oncoematologia IOV
Start Date
2019-07-02
Trial ID
NCT03731234
Treatments Being Tested
Study phase: Phase II Investigational product, dosage, and route of adminis...
Status
Completed
Location
Istituto di Ematologia e Oncologia Medica Seràgnoli
Start Date
TBD
Trial ID
NCT00850512
Patients treated for DLBCL are at high risk of developing AICD. This advers...
Status
Recruiting
Location
NL-Den Bosch-JBZ
Start Date
2024-08-15
Trial ID
NCT06220032
This study is a multicentric randomized trial evaluating the efficacy and s...
Status
Completed
Location
Université de Gent
Start Date
2003-12
Trial ID
NCT00144755
Treatments Being Tested
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growt...
Status
Completed
Location
Rigshospitalet, Department of Hematology
Start Date
2006-01-02
Trial ID
NCT00278408
The primary objective of the study is to demonstrate non-inferiority of lip...
Status
Completed
Location
Teva Investigational Site 32284
Start Date
2014-03-31
Trial ID
NCT02044276
Treatments Being Tested
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growt...
Status
Completed
Location
Haematologisch Onkologische Praxis
Start Date
2005-11
Trial ID
NCT00278421
Treatments Being Tested